SCHEMBL4631265

SCHEMBL4631265

Oc1ccc(CCCCCCCCCCCCc2ccc(O)cc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.77
ADRA2A P08913 3/20 0.77
SLC6A2 P23975 3/20 0.77
ADORA3 P0DMS8 2/20 0.77
TACR2 P21452 2/20 0.77
SLC6A4 P31645 2/20 0.77
SLC6A3 Q01959 2/20 0.77
KDM4E B2RXH2 2/20 0.77
ALDH1A1 P00352 2/20 0.77
LMNA P02545 1/20 0.77
SHBG P04278 1/20 0.77
TP53 P04637 1/20 0.77
CYP3A4 P08684 1/20 0.77
HSPD1 P10809 1/20 0.77
ADRB3 P13945 1/20 0.77
HTR2C P28335 1/20 0.77
HSPE1 P61604 1/20 0.77
HIF1A Q16665 1/20 0.77
TST Q16762 1/20 0.77
HSD17B10 Q99714 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9345284 1.00 ESR1 (0.77) ESR1ADRA2ASLC6A2ADORA3TACR2
SCHEMBL253453 1.00 ESR1 (0.77) ESR1ADRA2ASLC6A2ADORA3TACR2
SCHEMBL2777921 1.00 ESR1 (0.77) ESR1ADRA2ASLC6A2ADORA3TACR2
SCHEMBL9166790 1.00 ESR1 (0.77) ESR1ADRA2ASLC6A2ADORA3TACR2
SCHEMBL1447579 1.00 ESR1 (0.77) ESR1ADRA2ASLC6A2ADORA3TACR2
SCHEMBL8398450 1.00 ESR1 (0.77) ESR1ADRA2ASLC6A2ADORA3TACR2
SCHEMBL7784766 1.00 ESR1 (0.77) ESR1ADRA2ASLC6A2ADORA3TACR2
SCHEMBL9165397 1.00 ESR1 (0.77) ESR1ADRA2ASLC6A2ADORA3TACR2
SCHEMBL5684044 1.00 ESR1 (0.77) ESR1ADRA2ASLC6A2ADORA3TACR2
SCHEMBL449737 0.97 ESR1 (0.77) ESR1ADRA2ASLC6A2ADORA3TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117801242-A Preparation method of soluble thermotropic liquid crystal polyarylate fiber composite material 苏州光谨高新材料科技有限公司 2024-04-02 CN claimed
US-4439511-A Light-sensitive mixture based on O-naphthoquinone diazide ester of condensate of bisphenol and formaldehyde and light-sensitive copying material prepared therefrom HOECHST AKTIENGESELLSCHAFT (DE) 1984-03-27 US claimed
CN-117801242-A Preparation method of soluble thermotropic liquid crystal polyarylate fiber composite material 苏州光谨高新材料科技有限公司 2024-04-02 CN disclosed
CN-116964028-A Process for producing carbonyl halide 国立大学法人神户大学 2023-10-27 CN disclosed
US-20230332008-A1 PHENOL COMPOUND, CONDUCTIVE PASTE COMPOSITION, METHOD FOR PRODUCING CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-10-19 US disclosed
US-20230332008-A1 PHENOL COMPOUND, CONDUCTIVE PASTE COMPOSITION, METHOD FOR PRODUCING CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-10-19 US disclosed
EP-1937744-A1 PRODUCTION AND USE OF POLYCARBONATES COMPRISING SPECIAL PURIFIED, OLIGOMERIC EPOXY RESINS Bayer MaterialScience AG (DE) 2008-07-02 EP disclosed
EP-1922365-A1 POLYCARBONATE MOULDING COMPOUND EXHIBITING IMPROVED RHEOLOGICAL PROPERTIES Bayer MaterialScience AG (DE) 2008-05-21 EP disclosed
WO-2007042183-A1 PRODUCTION AND USE OF POLYCARBONATES COMPRISING SPECIAL PURIFIED, OLIGOMERIC EPOXY RESINS BAYER MATERIALSCIENCE AG (DE) 2007-04-19 WO disclosed
US-20070088107-A1 Production and use of polycarbonates with special purified, oligomeric epoxy resins BAYER MATERIALSCIENCE AG (DE) 2007-04-19 US disclosed
US-20070049705-A1 Polycarbonate molding compositions having improved rheological properties BAYER MATERIALSCIENCE AG 2007-03-01 US disclosed
EP-0703780-A4 USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE UNIV SYDNEY (AU) 1998-01-07 EP disclosed
EP-0546639-B1 A process for the preparation of bisphenols SHELL INT RESEARCH (NL) 1997-04-09 EP disclosed
CN-1124922-A Use of natural products and related synthetic compounds for the treatment of cardiovascular diseases UNIV SYDNEY (AU) 1996-06-19 CN disclosed
EP-0703780-A1 USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THE UNIVERSITY OF SYDNEY (AU) 1996-04-03 EP disclosed
WO-1994028886-A1 USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THE UNIVERSITY OF SYDNEY (AU) 1994-12-22 WO disclosed
EP-0546639-A1 A process for the preparation of bisphenols SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1993-06-16 EP disclosed
EP-0069966-B1 PHOTOSENSIBLE MIXTURE ON THE BASIS OF O-NAPHTHOQUINONE DIAZIDES, AND PHOTOSENSIBLE COPYING MATERIAL PRODUCED THEREFROM HOECHST AKTIENGESELLSCHAFT (DE) 1985-09-18 EP disclosed
US-4439511-A Light-sensitive mixture based on O-naphthoquinone diazide ester of condensate of bisphenol and formaldehyde and light-sensitive copying material prepared therefrom HOECHST AKTIENGESELLSCHAFT (DE) 1984-03-27 US disclosed
EP-0069966-A1 Photosensible mixture on the basis of o-naphthoquinone diazides, and photosensible copying material produced therefrom HOECHST AKTIENGESELLSCHAFT (DE) 1983-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230332008-A1 PHENOL COMPOUND, CONDUCTIVE PASTE COMPOSITION, METHOD FOR PRODUCING CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE COL1A1, MYB, HES1 ESR1 977/4885ADRA2A 2491/4885SLC6A2 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.